pacritinib
Sign in to saveAlso known as SB-1518, SB1518, Vonjo
Pacritinib, sold under the brand name Vonjo, is an anti-cancer medication used to treat myelofibrosis.
Key facts
- Drug.image
- Pacritinib skeletal.svg
- Drug.image_class
- skin-invert-image
- Drug.width
- 230
- Drug.tradename
- Vonjo
- Drug.DailyMedID
- Pacritinib
- Drug.routes_of_administration
- By mouth
- Drug.ATC_prefix
- L01
- Drug.ATC_suffix
- EJ03
- Drug.legal_US
- Rx-only
- Drug.CAS_number
- 937272-79-2
- Drug.PubChem
- 46216796
- Drug.DrugBank
- DB11697
- Drug.ChemSpiderID
- 28518965
- Drug.UNII
- G22N65IL3O
- Drug.KEGG
- D11768
- Drug.ChEBI
- 231350 =
- Drug.ChEMBL
- 2035187
- Drug.PDB_ligand
- 6T3
via Wikipedia infobox
~2 min read
Encyclopedic overview
6 sectionsContents
- Medical uses
- History
- Society and culture
- Names
- References
- External links
Pacritinib, sold under the brand name Vonjo, is an anti-cancer medication used to treat myelofibrosis.
It is a macrocyclic protein kinase inhibitor. It mainly inhibits Janus kinase 2 (JAK2) and Fms-like tyrosine kinase 3\CD135 (FLT3).
Excerpted from Wikipedia’s “pacritinib” article, available under the CC BY-SA 4.0 licence.